Guard Therapeutics: 25% of patients included in the Phase IIb POINTER trial
2025-01-09 17:23:00
Carnegie has published a new commissioned research report on Guard Therapeutics.
To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/guardtherapeutics/